期刊文献+

Akt特异性抑制剂MK2206诱导U937及RS4;11细胞凋亡及其机制 被引量:4

Inducing Effect of Akt Kinase Inhibitor MK2206 on Apoptosis in U937 Cells and RS4;11 Cells,and Its Mechanism
下载PDF
导出
摘要 目的:本研究探讨Akt激酶抑制剂MK2206对U937及RS4;11细胞增殖、凋亡的影响,并分析其可能的作用机制。方法:以不同浓度MK2206处理U937及RS4;11细胞24、48 h,用CCK-8法绘制细胞增殖曲线;Annexin V/7-氨基放线菌素D(7-AAD)双标记法分析细胞凋亡情况;流式细胞术检测细胞周期的变化;实时定量PCR检测Bax、Bcl-2、XIAP、CDK1、caspase-3基因mRNA表达的变化。结果:MK2206对U937及RS4;11细胞增殖具有抑制作用,且抑制效应呈一定的时间和剂量依赖性,U937细胞24、48 h的半数抑制浓度(IC50)分别为(0.48±0.15)和(0.09±0.01)μmol/L,RS4;11细胞24、48 h的半数抑制浓度(IC50)分别为(0.91±0.02)和(0.68±0.11)μmol/L。0.5μmol/L MK2206作用于U937细胞及1.0μmol/L MK2206作用于RS4;11细胞24 h、48 h,Annexin V/7-AAD标记的阳性细胞升高,U937细胞组24 h细胞凋亡率为(4.18±0.70)%,48 h细胞凋亡率为(22.53±4.67)%,均高于对照组的(1.35±0.34)%(P<0.05),且48 h细胞凋亡率较24 h更为明显(P<0.05);RS4;11细胞组24 h和48 h细胞凋亡率分别为(5.74±0.58)%和(10.07±1.24)%,均高于对照组的(1.32±0.31)%(P<0.05),且48 h细胞凋亡率较24 h更为明显(P<0.05)。流式细胞术检测细胞周期结果显示,U937细胞组G2/M期细胞比例为(96.78±9.11)%,高于对照组的(9.64±0.91)%(P<0.05);RS4;11细胞组G2/M期细胞比例为(14.19±3.82)%,高于对照组的(5.75±1.28)%(P<0.05)。荧光定量PCR检测结果示,两种细胞中Bax、caspase-3 mRNA相对表达水平升高,而Bcl-2、XIAP表达水平降低,同时伴CDK1 mRNA水平的减少,与各自对照组相比差异有统计学意义(P<0.05)。结论:MK2206能有效抑制U937及RS4;11细胞增殖及促进细胞凋亡,使细胞周期阻滞于G2/M期,其促凋亡机制与上调Bax与caspase-3基因表达、下调Bcl-2与XIAP基因表达有关,细胞周期G2/M期阻滞与CDK1基因表达水平下降有关。 Objective: This study was purposed to investigate the effect of Akt kinase inhibitor MK2206 on proliferation and apoptosis of U937 cells and RS4 ; 11 cells, and to explore its possible mechanism. Methods : U937 and RS4 ; 11 cells were cultured with different concentrations of MK2206 for 24 h and 48 h, and cell growth curve was analyzed by CCK-8; cell apoptosis was analyzed by Annexin V/7-AAD double labeling; cell cycle changes were analyzed by flow cytometry. The BAX,BCL-2 ,XIAP, CDK1, caspase-3 mRNA expressions were determined by real time PCR. Results: MK2206 significantly inhibited the growth of U937 and RS4 ; 11 cells in a time-and dose-dependent manner, and the ICs0 values of U937 cells for 24 h and 48 h were (0.48 ± 0.15 )μ mol/L and (0.09 ± 0.01 ) panol/L respectively, while IC50 values of RS4 ; 11 cells for 24 h and 48 h were( 0.91 ± 0.02 ) p, mol/L and ( 0.68±0.11 ) p, mol/L respectively. U937 were cultured with 0.5 μmol/L MK2206 and RS4 ; 11 cells were cultured with 1.0 p, mol/L MK2206 for 24 h and 48 h, and the both apoptosis rates were higher for 24 h or 48 h than that in control group( P 〈 0.05 ), meanwhile the apoptosis rates for 48 h were higher than 24 h. The results of cell cycle detection showed that the both cells were arrested in G2/M phase compared with control group. The real time PCR assay revealed that the expressions of BAX, caspase-3 mRNA in cells treated with MK2206 were increased, while BCL-2 ,XIAP, CDK1 were reduced compared with control group. Condusion : MK2206 can inhibit proliferation and induce apoptosis of U937 and RS4 ; 11 ceils, and the both cells are arrested in G2/M phase. The mechanism of promoting apoptosis may be related with up-regulating BAX, caspase-3 and down-regulating BCL-2 ,XIAP, meanwhile the cell cycle arrested in G2/M phase may be associated with down-regulating CDK1.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2015年第3期627-632,共6页 Journal of Experimental Hematology
基金 国家自然科学基金(81100349) 江苏省"六大人才高峰"项目(2011-WS-067)
关键词 MK2206 白血病 U937细胞 RS4 11细胞 细胞凋亡 MK2206 leukemia U937 cell RS4 11 cell apoptosis
  • 相关文献

参考文献13

  • 1Datta SR,Brunet A,Greenberg ME.Cellular survival:a play in three Akts.Genes Dev,1999;13(22):2905-2927.
  • 2Carnero A,Blanco-Aparicio C,Renner O,et al.The PTEN/PI3K/AKT signaling pathway in cancer,therapeutic implications.Curr Cancer Drug Targets,2008;8(3):187-198.
  • 3Li X1,Yang Q,Yu H,et al.LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-m TOR pathway.Oncotarget,2014;5(3):788-801.
  • 4Ko YH,Miyake H,Behnsawy HM,et al.Limited Significance of Activated Akt-Mammalian Target of Rapamycin Signaling Pathway in Prostate Cancer Progression.Urol Int,2014;93(2):146-151.
  • 5Agarwal E,Chaudhuri A,Leiphrakpam PD,et al.Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer.BMC Cancer,2014;14(1):145.
  • 6Piovan E,Yu J,Tosello V,Herranz D,et al.Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia.Cancer Cell,2013;24(6):766-776.
  • 7Bradford LS,Rauh-Hain A,Clark RM,et al.Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/m TOR signaling pathway in endometrial cancer.Gyneco Oncol,2014;133(2):346-352.
  • 8陈宏浦,黄轶群,马旭东.LY294002对Jeko-1细胞的增殖抑制及作用机制研究[J].中国实验血液学杂志,2013,21(5):1183-1186. 被引量:5
  • 9于文俊,杨文华,杨向东,史哲新,王兴丽,郝征,张佳.蝎毒多肽提取物对K562细胞PI3K和p-Akt信号蛋白表达及细胞增殖的影响[J].中国实验血液学杂志,2012,20(4):872-875. 被引量:4
  • 10Yap TA,Yan L,Patnaik A,et al.First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol,2011;29(35):4688-4695.

二级参考文献25

  • 1张之南,杨天楹.血液病学.北京:人民卫生出版社,2005:1249-1256.
  • 2Kurzrock R,Kantarjian HM,Druker BJ,et al.Philadelphiachromosome-positive leukemias:from basic mechanisms tomolecular Therapeutics.Ann Intern Med,2003;138(10):819-830.
  • 3Hirano I,Nakamura S,Yokota D.Depletion of pleckstrinhomology domain leucine-rich repeat protein phosphatase 1 and 2by Bcr/abl promotes chronic myelogenous leukemia cellproliferation through continuous phosphorylation of Akt isoforms.JBiol Chem,2009;284(33):22155-22165.
  • 4McCubrey JA,Steelman LS,Abrams SL,et al.Targeting survivalcascades induced by activation of Ras/Raf/MEK/ERK,PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemiatherapy.Leukemia,2008;22(4):708-722.
  • 5Blanco-Aparicio C,Pequeo B,Moneo V,et al.Inhibition ofphosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to themitochondria.Anticancer Drugs,2005;16(9):977-987.
  • 6Xu Q,Simpson SE,Scialla TJ,et al.Survival of acute myeloidleukemia cells requires PI3kinase activation.Blood,2003;102(3):972-980.
  • 7Montiel-Duarte C,Cordeu L,Agirre X,et al.Resistance toImatinib Mesylate-induced apoptosis in acute lymphoblasticleukemia is associated with PTEN down-regulation due to promoterhypermethylation.Leuk Res,2008;32(5):709-716.
  • 8Osaki M,Oshimura M,lto H.P13K-Akt pathway.Its functionsandl alterations in human cancer.Apoptosiy 2004;9(6):667-676.
  • 9Sale EM,Hodgkinson CP,Jones NP,et al.A new strategy forstudying protein kinase B and its three informs Role of proteinkinase-B in phosphorylating glycogen synthase kinase-3,tuberin,WNK1,and ATP citrate lyase.Biochemistry,2006;45(1):213-223.
  • 10Aichberger KJ,Mayerhofer M,Krauth MT,et al.Low-levelexpression of proapoptotic Bcl-2-interacting mediator in leukeniccells in patients with chronic myeloid leukemia;role of BCR/ABL,characterization of underlying signaling pathways,and expressionby novel pharmacologic compounds.Cancer Res,2005;65(20):9436-9444.

共引文献7

同被引文献31

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部